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Abstract Stem cell therapy is a promising treatment after
myocardial infarction (MI). A major problem in stem cell
therapy, however, is that only a small proportion of stem
cells applied to the heart can survive and differentiate into
cardiomyocytes. We hypothesized that fibronectin in the
heart after MI might positively affect stem cell adhesion
and proliferation at the site of injury. Therefore, we
investigated the kinetics of attachment and proliferation of
adipose-tissue-derived stem cells (ASC) on fibronectin and
analysed the time frame and localization of fibronectin
accumulation in the human heart after MI. ASCs were
seeded onto fibronectin-coated and uncoated culture wells.
The numbers of adhering ASC were quantified after various
incubation periods (5–30 min) by using DNA quantification
assays. The proliferation of ASC was quantified after
culturing ASC for various periods (0–9 days) by using
DNA assays. Fibronectin accumulation after MI was
quantified by immunohistochemical staining of heart
sections from 35 patients, after different infarction periods
(0–14 days old). We found that ASC attachment and
proliferation on fibronectin-coated culture wells was sig-
nificantly higher than on uncoated wells. Fibronectin
deposition was significantly increased from 12 h to 14 days
post-infarction, both in the infarction area and in the border-
zone, compared with the uninfarcted heart. Our results
suggest that a positive effect of fibronectin on stem cells in
the heart can only be achieved when stem cell therapy is
applied at least 12 h after MI, when the accumulation of
fibronectin occurs in the infarcted heart.
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Introduction
Cardiovascular diseases are a leading cause of morbidity and
mortality in the western world (Wang and Sjoquist 2006),
with heart failure attributable to myocardial infarction (MI)
being the most common aetiology (Lu et al. 2004). Heart
failure partly is caused by the loss of cardiomyocytes and
the limited capacity of spontaneous regeneration of the
heart. This results in the replacement of injured myocardi-
um by scar tissue, which adversely affects cardiac function
(Smits et al. 2005; Wang and Sjoquist 2006).
To reduce heart failure after MI, current therapeutic
strategies focus on the restoration of the blood flow to the
myocardium and on reducing cardiac remodelling by using
drug therapy (inhibitors of angiotensin-converting enzyme
Cell Tissue Res (2008) 332:289–298
DOI 10.1007/s00441-008-0573-0
This study was supported by the Institute for CardioVascular
Research of the VU Medical Centre in Amsterdam,
the Netherlands (ICaR-VU), project 200380.
A. van Dijk (*) :H. W. M. Niessen :W. Ursem :
F. J. van Milligen
Department of Pathology, ICaR-VU, VUUniversityMedical Centre,
Boelelaan 1117, 1081 HVAmsterdam, The Netherlands
e-mail: Annemieke.vandijk@vumc.nl
H. W. M. Niessen
Department of Cardiac Surgery, VU University Medical Centre,
Amsterdam, The Netherlands
J. W. R. Twisk
Department of Clinical Epidemiology and Biostatistics,
VU University Medical Centre, Amsterdam, The Netherlands
F. C. Visser
Department of Cardiology, VU University Medical Centre,
Amsterdam, The Netherlands
A. van Dijk :H. W. M. Niessen : F. C. Visser
ICaR-VU, Institute of Cardiovascular Research,
VU University Medical Centre, Amsterdam, The Netherlands
and beta blockers; Fraser et al. 2004). Although these
strategies significantly reduce mortality (Khalil et al. 2001;
Lange and Hillis 2002), they do not replace the lost
cardiomyocytes.
A promising tool to restore contractile function after
myocardial infarction is stem cell therapy. Stem cells not
only restore neovascularization, but also replace lost
cardiomyocytes, since they have the capacity to differenti-
ate into cardiomyocytes (Orlic et al. 2001; Strauer et al.
2002; Wang and Sjoquist 2006). However, to restore
contractile function of the heart effectively after MI,
sufficient stem cells need to attach to the infarcted area
and subsequently proliferate and differentiate into cardio-
myocytes, thereby replacing a substantial fraction of the
jeopardized cardiomyocytes. Unfortunately, recent studies
suggest that only a small proportion of stem cells applied to
the heart invade the infarcted area and finally differentiate
into cardiomyocytes. Furthermore, most of the applied stem
cells die within the first week after transplantation (Wang
and Sjoquist 2006; Zhang et al. 2001).
This high stem cell death rate is probably caused by the
inferior environment that is found in the heart after
myocardial infarction and into which the cells are trans-
planted; this poor environment is caused by the presence of
inflammatory mediators and ischemia (Azarnoush et al.
2005; Wang and Sjoquist 2006; Zhang et al. 2001).
Therefore, stem cell therapy has to be applied at that
moment after infarction when the environment is most
favourable for stem cell adhesion and cardiomyocyte
formation. However, to the best of our knowledge, this
ideal time frame has yet not been determined (Mishra
2005). In most animal studies, investigators apply stem
cells during the same operational procedure as the infarct
induction, whereas recent studies have shown that later time
points might be more favourable for the survival of the
stem cells (Bermejo et al. 2006; Lu et al. 2004; Wang and
Sjoquist 2006).
Homing, growth and differentiation of stem cells after
myocardial infarction is known to depend on several
environmental factors, including the presence of adhesion
factors at the site of injury (Chastain et al. 2006; Lu et al.
2004; Malek et al. 2006; Salasznyk et al. 2004; Wang and
Sjoquist 2006). Fibronectin has been demonstrated to
enhance the attachment of bone-marrow-derived stem cells
in vitro, compared with several other extracellular matrix
(ECM) molecules (Cool and Nurcombe 2005; Ogura et al.
2004). Fibronectin is a large molecular weight glycoprotein,
present at low levels in the ECM of the healthy heart (Heng
et al. 2004; Willems et al. 1996). In addition to the
influence of fibronectin on cell attachment, the presence
of fibronectin can also affect stem cell behaviour such as
migration and proliferation, both in vitro and in vivo (Tate
et al. 2002; van der Loo et al. 1998; Voermans et al. 1999;
Wijelath et al. 2004). However, the effect of fibronectin on
adipose-tissue-derived stem cells (ASC) has as yet not been
investigated. Therefore, we have examined whether fibro-
nectin stimulates the attachment of ASC and have com-
pared this with the attachment of ASC to other ECM
proteins that are normally expressed in the heart and that
are upregulated after acute MI (AMI), namely collagen type
1 and laminin (Deten et al. 2001; Morishita et al. 1996). We
have also investigated the effect of fibronectin on the
proliferation of ASC in vitro.
In vivo, fibronectin is strongly upregulated in the heart after
MI (Froen and Larsen 1995; Knowlton et al. 1992; Willems
et al. 1996). We have hypothesized that fibronectin serves as
an attractant for ASCs, thereby improving stem cell homing,
attachment and proliferation. Therefore, we have studied the
kinetics and the localization of fibronectin accumulation in
the human heart after MI in detail, in heart sections from 35
patients, representing various infarction periods.
Materials and methods
Adipose tissue donors
Human subcutaneous adipose tissue samples were obtained
as waste material after elective surgery and donated upon
informed consent of the patients from various clinics in
Amsterdam, The Netherlands. Adipose tissue was harvested
from the abdomen or hip and thigh region by using either
resection or tumescent liposuction. Five donors (age-range:
27–49 years) were included in this study.
Isolation of the stromal vascular fraction of adipose tissue
Adipose tissue was stored in sterile phosphate-buffered
saline (PBS) at 4°C and processed within 24 h after surgery
as described previously (Oedayrajsingh-Varma et al. 2006).
In brief, resected material was minced by using a surgical
scalp before processing. After extensive washes with PBS,
the ECM was enzymatically digested with 0.1% collage-
nase A (Roche Diagnostics, Mannheim, Germany) in PBS
containing 1% bovine serum albumin (BSA; Roche
Diagnostics) under intermittent shaking for 45 min at 37°C.
Then the material was washed with Dulbecco’s modified
Eagle’s medium (DMEM-glucose; BioWhittaker, Cambrex,
Verviers, Belgium) containing 10% fetal bovine serum (FBS)
and centrifuged for 10 min at 600g. The cell pellet was
resuspended in PBS and passed through a 200-μm mesh
(Braun/Beldico, Marche-en-Famenne, Belgium) to obtain a
single cell suspension. To remove contaminating erythro-
cytes, the cells were subjected to Ficoll density centrifugation
(lymphoprep, ρ=1.077 g/ml, osmolarity: 280±15 mOsm;
Axis-Shield, Oslo, Norway). The cell-containing interface
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was harvested and washed with DMEM containing 10%
FBS. Cells were frozen under “controlled rate” conditions
and stored in liquid nitrogen until needed in experiments.
Cell culture
Cells from the stromal vascular fraction were seeded at
1×105 cells/cm2 and cultured for several passages in
DMEM supplemented with 10% FBS, 100 U/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine (all from
Gibco, Invitrogen, Calif., USA; normal culture medium), in
a humidified atmosphere of 5% CO2 at 37°C. Media were
changed twice a week. When reaching 80%–90% conflu-
ency, cells were detached with 0.5 mM EDTA/0.05%
trypsin (Gibco, Invitrogen) for 5 min at 37°C and replated.
Attachment of ASC
To investigate attachment of ASC to different coatings,
culture-expanded cells (passages 3–6; p3-6) were seeded in
a 96-well culture plate at a density of 25,000 cells per well.
Wells were either uncoated or coated with fibronectin (5 or
0.5 μg/cm2; Roche Diagnostics), laminin (0.12 μg/cm2;
Roche Diagnostics) or collagen (2.5 μg/cm2, rat tail
collagen type I; BD Biosciences, Bedford, Mass., USA).
Cells were then allowed to attach undisturbed in a
humidified incubator (5% CO2, 37°C) for different incuba-
tion times (5 min, 10 min, 30 min), after which unattached
cells were removed by washing with PBS. To standardize
the conditions, all the conditions at the same timepoint were
added simultaneously to one microplate. The number of
attached cells was quantified by assaying for DNA with a
CyQUANT Cell Proliferation Assay Kit (Invitrogen)
according to the manufacturer’s protocol.
To achieve an in vitro situation more comparable to the
in vivo situation after AMI, attachment of ASC to cardiac
muscle cells and to fibronectin-coated cardiac muscle cells
was investigated. Cardiomyoblasts (H9c2, p18; ATCC,
Manassas, Va., USA) were seeded into 24-well culture
dishes, at a density of 10,000 cells per well, and when wells
were 70% confluent, cells were either coated with fibro-
nectin (0.5 or 5.0 μg/cm2) or remained uncoated. Then
culture-expanded cells (p3–p7) from four donors were
seeded into the culture dishes, at a density of 40,000 cells
per well. Cells were allowed to attach undisturbed in a
humidified incubator (5% CO2, 37°C) for various incuba-
tion times (5 min, 10 min, 30 min), after which the
unattached cells were removed by washing with PBS. The
cells were subsequently trypsinized, washed, centrifuged at
600g for 5 min, resuspended in 50 μl PBS and incubated
with anti-CD90 phycoerythrin-labelled antibody (1:20; BD
Biosciences Pharmingen, San Diego, Calif., USA) for 30
min on ice. The percentage of CD90-positive cells (ASC)
was quantified by using fluorescence-activated cell sorting
(FACS) analysis (FACScaliber, Becton Dickinson, San
Jose, Calif., USA).
Proliferation of ASC
To assess ASC proliferation on fibronectin-coated culture
dishes, culture-expanded cells (p3–p6) from three donors
were plated into 6-well culture plates, at a density of 25,000
cells per well, either coated with 5 μg/cm2 fibronectin or
uncoated, in normal culture medium. After a 1-day incu-
bation in a humidified incubator (5% CO2, 37°C), unat-
tached cells were removed by washing with PBS. Cells
were then allowed to proliferate for various incubation
times (0 days, 3 days, 6 days, 9 days). Cells were washed
with PBS to remove dead cells. The amount of living cells
removed by this washing was negligible (<0.5%). The
number of attached cells was quantified by assaying for
DNA with a CyQUANT Cell Proliferation Assay Kit
(Invitrogen) according to the manufacturer’s protocol.
Myocardial tissue from infarction
Myocardial tissue from 27 autopsied patients who had died
from AMI and from eight autopsied patients with no
cardiac lesions of any kind was obtained from the
Department of Pathology for authopsy, with approval
of the ethics committee of the VU Medical Centre,
Amsterdam. The use of left-over material after the
pathological examination is completed, is part of the
standard patient contract in our hospital. Heart tissue was
sampled as soon as possible, within 24 h of death.
Characterization of infarction phase
Recent AMI was defined by using macroscopic (lactate
dehydrogenase decolouration) and microscopic criteria to
estimate infarct duration and the viability of cardiomyo-
cytes in all myocardial tissue specimens (paraffin-wax-
embedded sections stained with haematoxylin and eosin).
Clinical data with respect to the duration of the infarction
corresponded to the time intervals of the various morpho-
logical phases of infarction. Jeopardized myocardium was
characterized by the intensity of eosinophilic staining of
involved myofibres, cell condensation, loss of nuclei and
cross striation and was visualized by complement (C3d)
staining. We defined heart tissue sections without micro-
scopic changes but with macroscopic lactate dehydrogenase
decolourization as a phase 1 infarct (3– to 12-h-old AMI),
infiltration of polymorphonuclear leucocytes as a phase
2 infarct (12-h to 5-day-old AMI) and infiltration of
lymphocytes and macrophages and fibrosis as a phase 3
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infarct (5– to 15-day-old AMI; Krijnen et al. 2003). Table 1
shows the distribution of the various infarct phases among
the different patients.
Immunohistochemistry
Myocardial tissue was fixed with 4% buffered formalde-
hyde and embedded in paraffin. Paraffin sections (3–4 μm)
were mounted on glass slides, dried, deparaffinized,
rehydrated, and then used for immunohistochemistry.
Sections were stained for fibronectin. Serial sections were
stained for complement factor C3d to define the micro-
scopical infarction area (Krijnen et al. 2003). All antibodies
used were from DakoCytomation (Glostrup, Denmark).
For C3d staining, antigen retrieval was performed by
boiling sections in 10 mM sodium citrate buffer, pH 6.0, for
10 min in a microwave oven. Sections were pre-incubated
with normal swine serum (1:10; DakoCytomation) for 10
min at room temperature, followed by an incubation with
rabbit antibodies against human C3d (1:1,000) for 1 h at
room temperature. The sections were then washed with
PBS and incubated with biotin-conjugated swine-anti-rabbit
antibodies (1:300) for 30 min, washed in PBS and
incubated with streptavidin-biotin complex/horseradish per-
oxidase (1:200) for 1 h. Staining was visualized by using
3,3′-diaminobenzidine (DAB; 0.1 mg/ml, 0.02% H2O2).
For fibronectin staining, antigen retrieval was performed
by incubating the sections with 0.1% pepsine-HCl for
30 min at 37°C. Sections were incubated with rabbit
antibodies against human fibronectin (1:18,000) for 1 h at
room temperature, followed by incubation with 100 μl
envision (ready for use kit, anti-Mouse IgG and anti-Rabbit
IgG) for 30 min at room temperature. Staining was
visualized with envision DAB (DakoCytomation). Finally,
the sections were counterstained with haematoxylin, dehy-
drated and cover-slipped. Control sections were incubated
with PBS instead of the primary antibody.
All slides were judged and scored for infarct age and
anatomical localization of fibronectin and C3d, as visualized
by immunohistochemical staining. The border-zone of the
infarct was defined as the area surrounding the microscopic
infarction area, as characterized by C3d staining. Since only
the fibronectin on the plasma membrane and in the ECM are
available for ASC attachment, fibronectin deposition was
scored separately for the ECM, plasma membrane and
intracellular components (nucleus and cytoplasm). The
extent of the fibronectin deposits was determined by
quantifying the mean surface area occupied by cardiomyo-
cytes positive for fibronectin and expressed as a percentage
of the total surface area of the sections in the infarcted region,
border-zone and non-infarcted areas. Areas were scored as
negative (0), 1%–5% of the cells positive (1), 6%–25%
positive (2), 26%–50% positive (3), 51%–75% positive
(4) or 76%–100% positive (5). Since positivity of fibronectin
in the ECM is difficult to quantify, fibronectin staining in
ECM was related to its intensity score as follows: negative
(0), minor positive (1), intermediate positive (2) or strongly
positive (3).
Statistics
Statistics were performed with the SPSS statistics program
(Windows version 9.0) and Graphpad Prism (version 4).
Attachment and proliferation data were analysed by using
Repeated Measures. Fibronectin accumulation was ana-
lysed by the Kruskal Wallis and the Dunn’s Multiple
Comparison Test. A P-value of less than 0.05 was con-
sidered to be significant.
Results
Attachment and proliferation of ASCs on fibronectin
To investigate the attachment of ASC to various ECM
molecules, the percentage of ASCs adhering to laminin,
fibronectin, collagen-1 and uncoated culture wells was
analysed. We monitored the number of ASCs in the culture
wells and compared this with the numbers of cells in
uncoated culture wells. As shown in Fig. 1, after 5 and
10 min of incubation, significantly higher numbers of
ASC were detected on fibronectin-coated culture wells
as compared with the uncoated culture wells (P<0.05).
This effect was dose-dependent, since a lower concen-
tration of fibronectin (0.5 μg/cm2 instead of 5.0 μg/cm2)
did not increase ASC attachment. Laminin and collagen-1
did not significantly affect ASC attachment, although
collagen-1 showed a trend towards increased attachment
of ASC. After 30 min, a plateau level seemed to be reached
for all conditions. This suggested that ASC adhered more
rapidly to fibronectin than to laminin, collagen or uncoated
culture wells.
Table 1 Characterization of the different infarct phases used in the
immunohistochemical study (LDH lactate dehydrogenase)
Infarction
phase
Number
of patients
Infarct
duration
Definition
0 8 No infarction Does not apply
1 11 3–12 h LDH decolourization,
without extravascular
neutrophilic granulocytes.
2 9 12 h–5 days Extravascular neutrophilic
granulocytes.
3 7 5–14 days Granulation tissue
formation
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To investigate the kinetics of ASC attachment in a
setting more comparable to the in vivo situation after AMI,
the percentage of ASCs adhering to fibronectin-coated and
uncoated cardiac muscle cells was monitored with time.
Numbers of adhered ASCs were quantified after 5, 10 and
30 min of attachment and are shown as the percentage of
total cells applied in Fig. 2. ASC rapidly adhered to the
fibronectin-coated cardiac muscle cells. This rapid attach-
ment was most prominent after 5 min of incubation, when
5 times more ASC attached to the fibronectin-coated cells
than to the uncoated cells (P<0.05). This effect was
independent of the dose of fibronectin, since the ASC also
attached rapidly to the cardiac muscle cells coated with a
lower concentration of fibronectin (0.5 μg/cm2 instead of
5.0 μg/cm2). On the uncoated cardiac muscle cells,
however, attachment was limited when compared with the
fibronectin-coated cells and increased only gradually the
first 10 min. For all conditions, a plateau level was reached
after 30 min of attachment. These findings suggested that
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Fig. 2 Kinetics of ASC adherence to fibronectin-coated (5 and
0.5 μg/cm2) and uncoated cardiac muscle cells monitored with time.
Numbers of adhered ASCs were quantified after 5 (a), 10 (b) and 30
(c) min of attachment. Results are expressed as the percentage of
applied cells. Error bars represent means±SEM (n=4, *P<0.05,
Repeated measures)
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Fig. 1 ASC adherence to laminin-coated, collagen-1 (col-1)-coated
and fibronectin (fibro)-coated (5 and 0.5 μg/cm2) and uncoated culture
wells monitored with time. Numbers of adhered ASCs were quantified
after 5 (a), 10 (b) and 30 (c) min of attachment. Results are expressed
as the percentage of applied cells. Error bars represent means±SEM
(n=4, *P<0.05, Repeated measures)
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ASC attached more rapidly on fibronectin-coated cardiac
muscle cells than to uncoated cardiac muscle cells.
To study the proliferation of ASCs on fibronectin, ASCs
were seeded in fibronectin-coated culture wells. Unattached
cells were washed away after 24 h (day 0). We monitored
the number of ASCs in the culture wells with time (days 0,
3, 6, 9) and compared this with the numbers of cells in
uncoated culture wells. Significantly higher numbers of
ASC were detected on fibronectin-coated culture wells
compared with the uncoated culture wells during the 9-day
culture period (P=0.012, Repeated measures, n=3; Fig. 3).
Fibronectin accumulation after infarction
Fibronectin accumulation after myocardial infarction was
investigated in heart sections from 35 patients, representing
various infarction periods (no infarction, infarction of 3–
12 h old, 12 h–5 days old, and 5–14 days old). To define
jeopardized cardiomyocytes and thus the microscopical
infarction area, we stained serial sections for complement
factor C3d (Fig. 4c). Fibronectin was found not only in
cardiomyocytes (plasma membrane, cytoplasm and nucle-
us; Fig. 4a), but also in the ECM (Fig. 4b). Fibronectin co-
localized with complement factor C3d but fibronectin
deposition was also found in the border-zone adjacent to
the infarction area (complement-negative). To analyse
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Fig. 3 Kinetics of ASC proliferation on fibronectin-coated (5 μg/cm2)
and uncoated culture wells. Numbers of adhered ASCs were
quantified after 0, 3, 6 and 9 days of culture by using the CyQUANT
cell proliferation assay. Results are expressed as percentage of cells,
compared to day 0, both for the fibronectin-coated and uncoated wells.
Error bars represent means±SEM. (n=3, p=0,012, Repeated meas-
ures)
Fig. 4 Localization of fibronec-
tin in myocardial infarction of
the human heart. Fibronectin
accumulation after myocardial
infarction was investigated in
heart sections representing dif-
ferent infarction periods. a High
power view of fibronectin de-
position in infarct phase 2. Fi-
bronectin depositions were
found on the plasma membrane
(arrow I ), in the nucleus (arrow
II ) and in the cytoplasm (arrow
III ) of jeopardized cardiomyo-
cytes. b Fibronectin depositions
in infarct phase 3 in the extra-
cellular matrix (ECM; arrow
IV ). c C3d deposition in infarct
phase 2 (+ jeopardized cardio-
myocytes, i.e. complement-pos-
itive cells, − complement-
negative cells). d Fibronectin
colocalization within C3d-posi-
tive areas in a serial section from
the same patient as in c, in
infarct phase 2. As a control,
AMI sections were incubated
with PBS instead of mAb and
gave no positive staining
(not shown)
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fibronectin depositions in the human heart after myocardial
infarction, we scored all sections for the extent and the
anatomical localization of fibronectin depositions. Notably,
in AMI phase 1, the border-zone and infarcted area could
not be analysed as such with the slides from the macro-
scopical infarction area, since it was not possible to identify
a microscopical infarction area clearly at this early phase, as
complement was then negative. As shown, the intensity of
fibronectin depositions in the ECM (Fig. 5) was signifi-
cantly increased at the site of myocardial infarction of AMI
phases 2 (P<0.01) and 3 (P<0.05) compared with the
uninfarcted heart. The extent of fibronectin deposition was
also increased in the border-zone of phases 2 and 3;
however, this increase was not statistically significant. In
phase 1 infarction and in the uninfarcted areas, no increase
in ECM fibronectin intensity score was found, when
compared with uninfarcted hearts (not shown).
We subsequently scored fibronectin positivity in the
cardiomyocytes. The extent of fibronectin deposition was
significantly increased in the infarcted area of AMI phase 2,
compared with controls, at the plasma membrane (P<0.05),
in the cytoplasm (P<0.001) and in the nucleus (P<0.05).
Fibronectin depositions were increased not only in the
infarcted area, but also in the border-zone of phase 2;
however, this increase was only statistically significant in
the nucleus when compared with the non-infarcted heart. In
AMI phase 3, no cardiomyocytes in the infarction area
could be analysed since this area no longer contains
cardiomyocytes in this stadium, but only granulation tissue.
The extent of fibronectin deposition was still significantly
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after myocardial infarction (IH immunohistochemical). a Area of
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Fig. 5 Fibronectin deposition in the ECM of the human heart after
myocardial infarction. Intensity of the fibronectin deposition in the
ECM was scored and compared with that of the non-infarcted heart
(stadium 0). Areas were scored negative (0), minor positive (1),
intermediate positive (2) or strongly positive (3). Error bars represent
means±SEM (*P<0.05, **P<0.01)
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increased in the border-zone of AMI phase 3 in the nucleus
and cytoplasm but was not positive on the plasma
membrane (Fig. 6a). Neither in AMI phase 1 (Fig. 6) nor
in non-infarcted areas (not shown) was an increase in
fibronectin positivity found in the cardiomyocytes when
compared with controls (Fig. 6).
Discussion
We hypothesized that accumulation of fibronectin in the
heart after MI might improve the fate of ASC after
transplantation in the heart. Therefore, we have studied the
effect of this protein on the attachment and proliferation of
ASC in vitro. In addition, we have investigated the time
course and the localization of the accumulation of fibronec-
tin after myocardial infarction in the human infarcted heart.
We have found that ASC attachment and proliferation on
fibronectin-coated plates is significantly increased compared
with that on uncoated plates (early attachment: P<0.05,
proliferation: P=0.009, Repeated measures, n=4) and that
attachment of ASC to cardiac muscle cells is significantly
increased when cells are coated with fibronectin (0.5 μg/cm2
and 5.0 μg/cm2), after 5 min of attachment. In the ECM of
the human heart, fibronectin depositions are significantly
increased at AMI phase 2 and phase 3 in the infarction area,
whereas fibronectin deposition in the cytoplasm, at the
plasma membrane and in the nucleus of cardiomyocytes is
significantly increased at AMI phase 2, but not in AMI phase
3, except for depositions in the nucleus.
When culture wells are coated with fibronectin, we have
found an increased attachment of ASC when compared with
uncoated plates, even though ASC are mesenchymal stem
cells that are defined by their strong attachment to plastic
culture wells (Wagner et al. 2005). We have also found that
neither laminin nor collagen-1 significantly increases the
attachment of ASC, unlike fibronectin, which does cause an
increase. These findings are comparable with studies of
Ogura et al. (2004) and Cool and Nurcombe (2005), in
which an increased attachment of human bone-marrow-
derived MSC to fibronectin-coated culture plates has been
found when compared with albumin-coated or other ECM-
coated culture plates. Ogura et al. (2004) have also reported
that attachment to fibronectin is most prominent within the
first 20 min of incubation. We now have shown that
fibronectin also improves the attachment of ASC.
In an experiment mimicking the in vivo situation after a
myocardial infarction, we have demonstrated that fibronec-
tin also increases the attachment of ASC to cardiac muscle
cells, even when a relatively low concentration of fibro-
nectin is used. These results are in agreement with our
hypothesis that fibronectin depositions will also increase
stem cell attachment in vivo, independent of fibronectin
concentration, underlining the importance of fibronectin in
stem cell transplantation.
In this study, we have additionally demonstrated a
significant increase in the proliferation of ASC cultured in
fibronectin-coated wells, compared with proliferation in
uncoated culture wells (P=0.012). This effect is most
prominent during the first 5 days of culture; thereafter, the
cells grow confluently and the effect diminishes. Cool and
Nurcombe (2005) have found no significant effect of
fibronectin on proliferation, although a trend is visible; this
might be caused by the timepoint of their study, since they
have only measured the difference in cell numbers at day 7,
or could be related to the source of stem cells.
Since the presence of fibronectin promotes ASC attachment
and proliferation in vitro in our study, we have hypothesized
that the presence of fibronectin in the heart after myocardial
infarction might positively affect stem cell adhesion and
proliferation at the site of injury. As such, stem cell therapy
would be most efficient when fibronectin depositions are high.
We have found an increase in the extent of fibronectin
depositions in cardiomyocytes during AMI phase 2, whereas
fibronectin deposition in the ECM is significantly increased in
the infarction area during AMI phase 2 and phase 3, when
compared with the uninfarcted heart.
These results are comparable with the findings of several
animal studies, in which increased fibronectin mRNA
expression has been demonstrated, together with increased
fibronectin deposition in the infarcted area as early as the
first day after infarct induction (Carlyle et al. 1997; Froen
and Larsen 1995; Knowlton et al. 1992; Shekhonin et al.
1990; Ulrich et al. 1997). Moreover, several studies have
shown increased deposition of fibronectin in the infarction
area after MI in human (Hu et al. 1996; Ishikawa et al.
2000, 2003; Ortmann et al. 2000; Willems et al. 1996).
However, none of these studies have scored the fibronectin
depositions as accurately as we have during the different
infarction phases, i.e. by using complement to define the
microscopic infarction area, by differentiating between
infarction area and border-zone and by separately scoring
the ECM and the various anatomical locations in the cells.
We have studied the various anatomical locations of
fibronectin depositions separately, since theoretically only
fibronectin on the plasma membrane and in the ECM
should play a direct role in stem cell attachment. Although
fibronectin has been detected on the ECM and the plasma
membrane of cardiomyocytes, depositions in the cytoplasm
and the nuclei are more widespread than on the plasma
membrane. These strong depositions in the nucleus and
cytoplasm have also been reported by Ishikawa et al. (2000);
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however, they have only described these nuclear depositions
and not scored them.
Notably, we have found that the extent of fibronectin
depositions in the heart is only increased in the infarcted
area and the border-zone, and not in the non-infarcted areas.
This is an important observation, since stem cell attachment
and differentiation is only desirable in the infarcted area and
the area surrounding it for stem cell therapy. In accordance
with this finding, Tran et al. (2006) have indeed shown that
rat bone marrow MSC are retained better in the infarcted
area, when compared with the intact myocardium.
Several other studies have also investigated the time
frame after MI with respect to when best to apply stem cell
therapy, both in animal models and human stem cell
transplantation studies, by investigating molecular events
and stem cell retention at the site of infarction (Bermejo
et al. 2006; Lu et al. 2004; Ma et al. 2005). These studies
suggest that stem cell therapy should neither be applied
during the acute inflammation phase (within 1 day after
infarction), nor after a period longer than 2 weeks when
scar tissue has been formed. In agreement with this
suggestion, our results indicate that a putative effect of
fibronectin on stem cell therapy can only be achieved when
stem cell therapy is applied more than 12 h but within
14 days after infarction.
In conclusion, we have shown, for the first time, that
fibronectin improves ASC attachment and proliferation. To
achieve a positive effect of fibronectin on stem cell therapy
after AMI in the heart, this therapy should be applied when
fibronectin depositions in the heart are high. We have
accurately scored fibronectin deposition in the human heart
after AMI and found that the fibronectin intensity score
significantly increases from 12 h after MI in both the
infarction area and the border-zone.
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